Real-world prevalence of potential drug–drug interactions associated with oral advanced therapies indicated for ulcerative colitis

Comorbidities and polypharmacy among patients with UC pose a high risk of DDIs for oral advanced therapies and required pre-treatment clinical assessments can be complicated. This justifies a thorough review of patient profiles for prescribers considering novel treatment options.